Level Four Advisory Services’s Pacira BioSciences PCRX Stock Holding History

Level Four Advisory Services’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,812	Closed	-$805K	–	572
2022 Q2	$805K	Buy	13,812 +318	+2%	+$20.8K	0.08%	254
2022 Q1	$1.03M	Buy	+13,494	New	+$900K	0.08%	235
2021 Q4	–	Sell	-7,846	Closed	-$439K	–	667
2021 Q3	$439K	Buy	7,846 +1,282	+20%	+$73.9K	0.05%	314
2021 Q2	$398K	Buy	6,564 +863	+15%	+$54.6K	0.03%	464
2021 Q1	$400K	Buy	+5,701	New	+$407K	0.03%	426

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Level Four Advisory Services's PCRX Position: Q3 2022 in Review

Level Four Advisory Services sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 13,812 shares — an estimated $805K sold.

Level Four Advisory Services first reported a position in PCRX in Q1 2021 and held it in 5 quarters. The position peaked at $1.03M in Q1 2022. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

Level Four Advisory Services reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
Level Four Advisory Services sold 13,812 Pacira BioSciences shares in Q3 2022, an estimated $805K.
Level Four Advisory Services first reported a position in Pacira BioSciences in Q1 2021 and held it in 5 quarters.
Level Four Advisory Services's Pacira BioSciences position peaked at $1.03M in Q1 2022.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Level Four Advisory Services's 13F filing for Q3 2022, filed 7 Nov 2022.